USRE33465E - Method for reducing the duration of the common cold - Google Patents

Method for reducing the duration of the common cold Download PDF

Info

Publication number
USRE33465E
USRE33465E US06848457 US84845786A USRE33465E US RE33465 E USRE33465 E US RE33465E US 06848457 US06848457 US 06848457 US 84845786 A US84845786 A US 84845786A US RE33465 E USRE33465 E US RE33465E
Authority
US
Grant status
Grant
Patent type
Prior art keywords
iaddend
iadd
method
zinc
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06848457
Inventor
George A. Eby, III
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/315Zinc compounds

Abstract

The invention disclosed and claimed is a method to reduce duration of common colds in humans as evinced by reduction of duration of 10 common cold symptoms through use of zinc gluconate topically and frequently applied to the oral mucosa. The invention improves upon the prior art using zinc intranasally as an astringent and decongestant in treatment of common colds. Results of a clinical study are presented in support of disclosure and claims.

Description

A continuation-in-part of "A Rapid Acting Treatment for the Common Cold" Ser. No. 288,750 filed .[.7/31/81.]..Iadd.July 31, 1981.Iaddend., now abandoned.Iadd., which was a continuation-in-part of "Treatments for Viral Infections, Including the Common Cold, and Allergies" Ser. No. 222,620 filed Jan. 5, 1981, now abandoned.Iaddend..

FIELD OF INVENTION

This invention relates to a method for reducing the duration of the common cold in humans.

BACKGROUND

The art of managing viral upper respiratory infections commonly called common colds has not been adequate. Common colds are the most common acute illness in the United States and account for about one-half of all lost school days and lost work days. An estimated one billion colds occur in the United States each year. Thus, there can be no question as to the need for a safe, simple, inexpensive, effective and available treatment to minimize or eliminate this important and costly public health problem.

Heretofore, treatment of common colds involved use of symptomatic therapy. Such therapy did not reduce duration of common colds. For example, with or without treatment, duration of 50% of the common colds caused by rhinoviruses remained at 7 days. Primary common colds symptoms are nasal drainage and nasal congestion. Secondary symptoms often accompanying primary symptoms include: headache, fever, myalgia, sneezing, sore throat, scratchy throat, cough and hoarseness. The prior art teaches individual treatment of each symptom as needed to ameliorate symptoms during their association with a common cold, rather than teaches treatment of the common cold to reduce the duration of all symptoms associated with them.

PRIOR ART

It has been established in vitro that zinc ions can inhibit replication of a few of the many antigenically different rhinoviruses. The concentration of zinc ions required to be antirhinoviral is 10-4 M or greater which is 10 times or greater than the zinc ionic concentration found in human serum. But other in vitro studies have demonstrated that inhibitory effects of zinc on rhinoviruses are reversible and provide no lasting effect once the zinc ions are removed from the medium. .[.According to the latter studies, when zinc is removed from rhinoviruses, they resume their replication and again become fully infective..]. .Iadd.According to the latter studies, when zinc is removed from rhinoviruses, then resume their replication and again becomes fully infective. .Iaddend.The best use .[.fo.]. .Iadd.for .Iaddend.zinc in activities involving the rhinoviruses was suggested to be as a method to temporarily or reversibly inhibit rhinovirus replication in laboratory experiments. Since the antirhinoviral effect was observed to be reversible and since the inhibitory effects had been demonstrated in only a few of the antigenically different viruses known to cause the common cold, zinc was not considered to be a suitable antirhinoviral agent for the treatment of the common cold in humans.

It has been established that zinc can provide an astringent and decongestant effect in common cold treatment. Zinc inhibits the release of histamine from mast cells and basophils. Histamine is a mediator of two primary common cold symptoms. The effect of zinc in inhibiting the release of histamine from mast cells and basophils produces a reduction in histamine mediated nasal drainage and nasal congestion, which might be considered as astringent-like and decongestant. A technique used earlier in this century to provide astringent and decongestant effects in the treatment of common colds requires that 4 to 10 drops of a 0.2% to 2.0% zinc borate aqueous suspension be applied by spray, instillation or Dowling packing into each nostril or eye several times per day. Such an intranasal method operates only to relieve the treatment human from certain discomfort associated with the congestion symptoms. But it can now be disclosed that the low dosages of zinc and the method of application only brings temporary relief, perhaps because natural circulation removes zinc ions from the locus of the treatment more rapidly than the low application rate of zinc ions by the dosages replaces them. Because it has been established in vitro that zinc ions can inhibit replication of rhinoviruses, one may theorize that a low dosage of zinc may produce a zinc ion concentration that may or may not reach antiviral concentrations and that a method of application that does not maintain a sufficiently high level of zinc ions in the locus of treatment would not prevent continued viral replications. Regardless of a theoretical justification for a method of .[.decreasing1Θ .Iadd.increasing .Iaddend.zinc ion concentration, the astringent-like and decongestant effects of the low zinc dosages under the prior art methods of application cease when the treatment is discontinued before the cold has run its normal, untreated duration.

OBJECTIVE OF INVENTION

Accordingly, the objective of this invention is to correct deficiencies of the prior art in treatment of common colds through use of a method that significantly reduces duration of common colds in humans.

SUMMARY OF INVENTION

This invention relates to a new treatment that shortens duration of common colds through use of zinc compounds applied in a manner and at a frequency so as to cause a sustained, above normal concentration of zinc ions in the virally infected tissues until no common cold symptoms remain and without relapse of any common cold symptom.

DETAILED DESCRIPTION OF INVENTION

The invention disclosed and claimed is a method to reduce duration of common colds in humans as evinced by reduction of duration of 10 common cold symptoms defined as being: nasal drainage, nasal obstruction, headache, fever, myalgia, sneezing, sore throat, scratchy throat, cough and hoarseness with each symptom, when present, being a result of a viral upper respiratory infection. Such method involves administration of pharmaceutically acceptable zinc compounds topically applied to oral, pharyngeal and/or nasal mucosal membranes by a manner that raises the concentration of zinc ions in virally infected areas. Those concentrations are maintained for a period of time until all common cold symptoms are eliminated without .[.release.]. .Iadd.relapse.Iaddend.. Means of application include, but are not limited to the following direct, indirect, carrier, and special means or any combination of means. Direct application of zinc compounds may be by nasal sprays, nasal drops, nasal ointments, nasal washes, nasal injections, packings, or indirectly through use of throat troches or lozenges, or through use of mouth washes or gargles, or through the use of inhalants or ointments applied to the nasal nares, the bridge of the nose, or the face or any combination of these and similar methods of application. Carriers such as dimethyl sulfoxide and other special methods such as oral ingestion or parenteral introduction of zinc compounds where such treatment allows elevation of zinc ionic concentration in virally infected areas may be used as needed and given by any means of administration. The forms in which the zinc compounds may be administered include but are not limited to lozenges, troches, candies, injectants, chewing gums, tablets, powders, sprays, liquids, ointments, and aerosols. Pharmaceutically acceptable zinc compounds in dosages from 2 to 200 milligrams of zinc include but are not limited to zinc gluconate, zinc ascorbate, zinc citrate, zinc oxide, zinc acetate, zinc picolinate, zinc transferrin, zinc orotate and zinc aspartate.

AN OPERATIONAL METHOD TO DEMONSTRATE INVENTION

The following Treatment Instructions, prepared by the applicant, represent one way of using zinc compounds to reduce duration of common colds. The instruction were used in a random, double-blind, clinically controlled study in the office of Dr. William W. Halcomb, M.D., D.O. during the autumn of 1981 in Austin, Tex. Each tablet used in the double-blind study contained either 23 milligrams of zinc from zinc gluconate or 50 milligrams of calcium lactate as the placebo.

TREATMENT INSTRUCTIONS

At the office visit, patients are each given a bottle of tablets to use to treat the common cold. The patient dissolves the first tablet in the mouth so as to saturate the oral mucosa (lining of the mouth, tongue and throat) and then a second tablet immediately thereafter. Continue treatment after leaving the office during wakeful hours by dissolving in the mouth the appropriate number of tablets following the treatment schedule for age group of patient:

______________________________________Age    Tablets/   Schedule forGroup  Treatment  Treatment  Maximum Daily Dosage______________________________________Adult  1          Each 2 hours                        12 tabletsYouth  1          Each 2 hours                        9 tabletsChild  1/2        Each 2 hours                        6 tablets______________________________________

Patients should not wash down medication with either food, drink or mouthwashes. Patients should be treated immediately prior to bedtime and during the night when awake. After all symptoms have been absent for six hours, the patient may stop treatment.

RESULTS OF STUDY USING TREATMENT INSTRUCTIONS TO DEMONSTRATE INVENTION SO DESCRIBED

Data collected during the study indicate that the group treated with zinc gluconate lozenges recovered faster than did the group treated with placebo. The placebo-treated group responded at a rate identical to untreated rhinovirus common cold patients described in medical literature. The following paragraph is the abstract from a manuscript entitled "Reduction in Duration of Common Colds by Zinc Gluconate Lozenges in a Double-Blind Study" which was prepared from data obtaining during the study and was published in Antimicrobial Agents and Chemotherapy, volume 25, pages 20-24, 1984.

As a possible treatment for common colds, we tested zinc gluconate lozenges in a double-blind, placebo-controlled, clinical trial. One 23-mg zinc lozenge or matched placebo was dissolved in the mouth every 2 wakeful hours after an initial double dose. After 7 days 86% of 37 zinc-treated subjects were asymptomatic, compared with only 46% of 28 placebo-treated subjects (P=0.0005). Side effects or complaints were usually minor and consisted mainly of objectionable taste and mouth irritation. Zinc lozenges shortened the average duration of common colds by about 7 days.

Not only was duration of common colds treated with zinc significantly shorter, but duration of 10 common cold symptoms was shorter and severity of symptoms was also reduced. Duration of common colds is defined as the longest period of time in which any one, or more, of the 10 common cold symptoms remained.

CONTRAINDICATIONS TO TREATMENT

There are no known contraindications to the treatment.

Claims (8)

What is claimed is:
1. The method of administering an agent to reduce duration of common cold symptoms in humans, which includes reducing the duration of nasal drainage, nasal congestion, headache, fever, myalgia, sneezing, sore throat, scratchy throat, cough, and .[.horseness.]. .Iadd.hoarseness .Iaddend.when such symptoms evince existence of a common cold, comprising:
applying, in the form of a lozenge, zinc gluconate to the oral mucosa of a human in need of treatment;
permitting zinc to remain in contact with the mucosa for a period of time necessary for lozenges to dissolve;
and applying additional dosages of zinc until the symptoms have disappeared.
2. The method according to claim 1 wherein dosages of zinc gluconate each contain 2 to 50 milligrams of zinc.
3. The method according to claim 1 wherein the first dosage of zinc gluconate is double that of additional dosages, additional dosages each consists of a single lozenge given two hours after a previously applied dosage, and all dosages are applied during the waking hours of the human in need of treatment. .Iadd.
4. A method for treating the common cold comprising:
(a) applying an effective dosage of zinc gluconate to the oral mucosa of a human in need of treatment;
(b) permitting the zinc thereof to remain in contact with the oral mucosa for a period of time necessary for it to saturate the oral mucosa; and
(c) applying additional dosages to zinc gluconate in like fashion until the cold has been treated. .Iaddend. .Iadd.
5. The according to claim 4 wherein a first dosage of zinc gluconate is double that of additional dosages, additional dosages each consisting of a single dosage given approximately two hours after a previously applied dosage. .Iaddend. .Iadd.6. The method according to claim 4 wherein dosages of zinc gluconate each contain between about 2 and about 200 milligrams of zinc. .Iaddend. .Iadd.7. The method according to claim 6 wherein dosages of zinc gluconate each contain between about 2 and about 50 milligrams of zinc. .Iaddend. .Iadd.8. The method of claim 4 wherein the dosage form is a solid dosage form, and the zinc is permitted to remain in contact with the oral mucosa for a period of time necessary for it to dissolve.
.Iaddend. .Iadd.9. The method of claim 8 wherein the dosage form is a candy. .Iaddend. .Iadd.10. The method of claim 8 wherein the dosage form is a chewing gum. .Iaddend. .Iadd.11. The method of claim 8 wherein the dosage form is a lozenge. .Iaddend. .Iadd.12. The method of claim 8 wherein the dosage form is a troche. .Iaddend. .Iadd.13. The method of claim 8 wherein the dosage form is a tablet. .Iaddend. .Iadd.14. The method of claim 8 wherein the dosage form is a powder. .Iaddend. .Iadd.15. The method of claim 4 wherein the dosage form is an aerosol. .Iaddend. .Iadd.16. The method of claim 4 wherein the dosage form is a liquid. .Iaddend. .Iadd.17. The method of claim 16 wherein the liquid is a liquid spray. .Iaddend. .Iadd.18. A method for treating symptoms commonly associated with the common cold, the symptoms including nasal drainage, nasal congestion, headache, fever, myalgia, sneezing, sore throat, scratchy throat, cough or hoarseness to reduce the duration or severity thereof comprising:
(a) applying an effective dosage of zinc gluconate to the oral mucosa of a human in need of treatment;
(b) permitting the zinc thereof to remain in contact with the oral mucosa for a period of time necessary for it to saturate the oral mucosa; and
(c) applying additional dosages of zinc gluconate in like fashion until the
severity or duration of the symptom has been reduced. .Iaddend. .Iadd.19. The method according to claim 18 wherein a first dosage of zinc gluconate is double that of additional dosages, additional dosages each consisting of a single dosage given approximately two hours after a previously applied dosage. .Iaddend. .Iadd.20. The method according to claim 18 wherein dosages of zinc gluconate each contain between about 2 and about 200 milligrams of zinc. .Iaddend. .Iadd.21. The method according to claim 20 wherein dosages of zinc gluconate each contain between about 2 and about 50 milligrams of zinc. .Iaddend. .Iadd.22. The method of claim 18 wherein the dosage form is a solid dosage form, and the zinc is permitted to remain in contact with the oral mucosa for a period of time necessary
for it to dissolve. .Iaddend. .Iadd.23. The method of claim 22 wherein the dosage form is a candy. .Iaddend. .Iadd.24. The method of claim 22 wherein the dosage form is a chewing gum. .Iaddend. .Iadd.25. The method of claim 22 wherein the dosage form is a lozenge. .Iaddend. .Iadd.26. The method of claim 22 wherein the dosage form is a troche. .Iaddend. .Iadd.27. The method of claim 22 wherein the dosage form is a tablet. .Iaddend. .Iadd.28. The method of claim 22 wherein the dosage form is a powder. .Iaddend. .Iadd.29. The method of claim 18 wherein the dosage form is an aerosol. .Iaddend. .Iadd.30. The method of claim 18 wherein the dosage form is a liquid. .Iaddend. .Iadd.31. The method of claim 30 wherein the dosage form is a liquid spray. .Iaddend.
US06848457 1981-07-31 1986-04-04 Method for reducing the duration of the common cold Expired - Lifetime USRE33465E (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US28875081 true 1981-07-31 1981-07-31
US06848457 USRE33465E (en) 1981-07-31 1986-04-04 Method for reducing the duration of the common cold

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06848457 USRE33465E (en) 1981-07-31 1986-04-04 Method for reducing the duration of the common cold

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US28875081 Continuation-In-Part 1981-07-31 1981-07-31
US06378479 Reissue US4503070A (en) 1981-07-31 1982-05-14 Method for reducing the duration of the common cold

Publications (1)

Publication Number Publication Date
USRE33465E true USRE33465E (en) 1990-11-27

Family

ID=26965216

Family Applications (1)

Application Number Title Priority Date Filing Date
US06848457 Expired - Lifetime USRE33465E (en) 1981-07-31 1986-04-04 Method for reducing the duration of the common cold

Country Status (1)

Country Link
US (1) USRE33465E (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095035A (en) * 1981-07-31 1992-03-10 Eby Iii George A Flavor stable zinc acetate compositions for oral absorption
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US5409905A (en) * 1981-01-05 1995-04-25 Eby, Iii; George A. Cure for commond cold
US5626831A (en) * 1995-12-20 1997-05-06 Van Moerkerken; Arthur Method for relief and prevention of common cold, and compositions
US5728404A (en) * 1992-02-26 1998-03-17 Henkel Kommanditgesellschaft Auf Aktien Virucidal disinfectant
US5875799A (en) * 1997-09-23 1999-03-02 Advanced Medical Instruments, Inc. Therapeutic dental floss for treating systemic diseases
US6365624B1 (en) 1998-09-01 2002-04-02 Gel Tech, L.L.C. Method and composition for delivering zinc to the nasal membrane
US6416744B1 (en) * 2001-06-21 2002-07-09 Colgate Palmolive Company Tooth whitening chewing gum
US20040033260A1 (en) * 1999-10-19 2004-02-19 The Procter & Gamble Company Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc
US20050043400A1 (en) * 2003-04-30 2005-02-24 Tim Clarot Oral composition to reduce cold symptoms and duration of same
US7115275B2 (en) 2002-09-16 2006-10-03 Zicam, Llc System for delivering a composition to the nasal membrane and method of using same
US20070092583A1 (en) * 2003-04-30 2007-04-26 Tim Clarot Cold remedy composition comprising zinc salts
US20070092552A1 (en) * 2003-04-30 2007-04-26 Tim Clarot Chewable lozenge cold remedy composition and method for making same
US20070293466A1 (en) * 2004-11-03 2007-12-20 Thompson Robert C Antimicrobial Chelates
US20090081294A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained release dosage form for lubricating an oral cavity
US20090081291A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User
US8236348B2 (en) 2003-02-04 2012-08-07 Bennes, Inc. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
US9034401B1 (en) 2014-01-23 2015-05-19 Matrixx Initiatives, Inc. Pharmaceutical compositions comprising plant extracts and methods for reducing duration of a common cold using same
US9565858B2 (en) 2012-07-02 2017-02-14 Reckitt Benckiser Llc Aqueous alcoholic microbicidal compositions comprising zinc ions
US9615582B2 (en) 2012-07-02 2017-04-11 Reckitt Benckiser Llc Pressurized, sprayable aqueous alcoholic microbicidal compositions comprising zinc ions
US9707162B2 (en) 2012-11-30 2017-07-18 Reckitt & Colman (Overseas) Limited Microbicidal personal care compositions comprising metal ions
US9775356B2 (en) 2012-07-02 2017-10-03 Reckitt Benckiser Llc Aqueous alcoholic microbicidal compositions comprising zinc ions

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU240182A1 *
US944738A (en) * 1909-08-16 1909-12-28 Windeler Loose Medicament for diseases of the mucous membrane.
US1488097A (en) * 1922-03-09 1924-03-25 Henry N Creger Dentifrice
US1861189A (en) * 1929-12-20 1932-05-31 Pfizer Charles & Co Dentifrice
US2527686A (en) * 1945-12-26 1950-10-31 Max H Sandberg Mouthwash
US3622662A (en) * 1969-04-21 1971-11-23 Colgate Palmolive Co Stable dental cream
US4146606A (en) * 1977-05-27 1979-03-27 Reiichi Yamaga Pharmaceutical compositions for dental use
US4367218A (en) * 1979-09-06 1983-01-04 Jacobson Jerry I Anti-caries oral rinse
US4444755A (en) * 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
US4469674A (en) * 1981-09-03 1984-09-04 Richardson-Vicks Inc. Stable oral compositions containing zinc and fluoride compounds
US4503070A (en) * 1981-07-31 1985-03-05 Eby Iii George A Method for reducing the duration of the common cold

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU240182A1 *
US944738A (en) * 1909-08-16 1909-12-28 Windeler Loose Medicament for diseases of the mucous membrane.
US1488097A (en) * 1922-03-09 1924-03-25 Henry N Creger Dentifrice
US1861189A (en) * 1929-12-20 1932-05-31 Pfizer Charles & Co Dentifrice
US2527686A (en) * 1945-12-26 1950-10-31 Max H Sandberg Mouthwash
US3622662A (en) * 1969-04-21 1971-11-23 Colgate Palmolive Co Stable dental cream
US4146606A (en) * 1977-05-27 1979-03-27 Reiichi Yamaga Pharmaceutical compositions for dental use
US4444755A (en) * 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
US4367218A (en) * 1979-09-06 1983-01-04 Jacobson Jerry I Anti-caries oral rinse
US4503070A (en) * 1981-07-31 1985-03-05 Eby Iii George A Method for reducing the duration of the common cold
US4469674A (en) * 1981-09-03 1984-09-04 Richardson-Vicks Inc. Stable oral compositions containing zinc and fluoride compounds

Non-Patent Citations (70)

* Cited by examiner, † Cited by third party
Title
"Idoxuridine and Some Other Antiviral Agents" (1982), Martindale, The Extra Pharmacopocia, 28th Edition, pp. 820-827.
"Zinc vs. Colds" (1984), Austin American Statesman, Dec. 2, 1984, p. A15.
"Zinc Zaps Common Cold" (1987), The Evening Wellington, New Zealand.
1948 Quarterly Cumulative Index Medicus, vol. 44, p. 797. *
Akzo Chemie "Gluconates", pp. 5-15.
Akzo Chemie Gluconates , pp. 5 15. *
Al Nakib et al. (1987), Jrnl. Antimicrob. Chemother., 20:893. *
Al Nakib et al., Prophylaxis and Treatment of Rhinovirus Colds with Zinc Gluconate Lozenges , Jrnl. Antimicrob. Chemother., 20(6):893 901, 1987. *
Al-Nakib et al. (1987), Jrnl. Antimicrob. Chemother., 20:893.
Al-Nakib et al., "Prophylaxis and Treatment of Rhinovirus Colds with Zinc Gluconate Lozenges", Jrnl. Antimicrob. Chemother., 20(6):893-901, 1987.
Andermann et al. (1982), Eur. Jrnl. Drug Metab. Pharma., 7(8):233. *
Anderson et al. (1983), "Viral Respiratory Illnesses", Medical Clinics of North America, 67(5):1009.
Anderson et al. (1983), Viral Respiratory Illnesses , Medical Clinics of North America, 67(5):1009. *
Bailey, et al. (1937), Brit. Med. Jrnl., Apr. 17, 1937, p. 808. *
Butterworth et al. (1976), Arch. Virol., 51:109. *
Carter et al., Chemotherapy of Cancer, 2nd ed., John Wiley & Sons, pp. 26 29. *
Carter et al., Chemotherapy of Cancer, 2nd ed., John Wiley & Sons, pp. 26-29.
Chapter 57, "Antiviral Chemotherapy & Prophylaxis," in Review of Medical Pharmacology, 7th Edition, Meyers et al. eds., pp. 589-592.
Chapter 57, Antiviral Chemotherapy & Prophylaxis, in Review of Medical Pharmacology, 7th Edition, Meyers et al. eds., pp. 589 592. *
Christison, A Dictionary, Philadelphia; Lee and Blanchard, 1948, p. 983. *
Couch (1984), Jrnl. Infect. Dis., 150(2):174. *
Eby (1988), Antimicrob. Agents Chemother., 32:606. *
Eby et al. (1984), Antimicrob. Agents Chemother., 25(1):20. *
Eby et al., "Effect of Zinc Orotate Lozenges with Zinc Gluconate Nasal Spray in Common Cold Treatment--a Double Blind Study," unpublished.
Eby et al., Effect of Zinc Orotate Lozenges with Zinc Gluconate Nasal Spray in Common Cold Treatment a Double Blind Study, unpublished. *
Farr et al. (1987), Antimicrob. Agents Chemother., 31:1183. *
Farr et al. (1988), Antimicrob. Agents Chemother., 32:607. *
Giron (1982), Proc. Soc. Exp. Biol. Med., 170:25. *
Godfrey (1988), Antimicrob. Agents Chemother., 32:605. *
Gutman (1941) Modern Drug Encyclopedia. *
Gutman, Modern Drug Encyclopedia, 1941, p. 731. *
Handbook of Non Prescription Drugs, 6th Edition, p. 317. *
Handbook of Non-Prescription Drugs, 6th Edition, p. 317.
Harmon et al. (1976), Proc. Soc. Exp. Biol. Med., 152:598. *
Hayden et al. (1982), Antimicrob. Agents Chemother., 21(6):892. *
Hayden et al. (1984), Jrnl. Infect. Dis., 150(2):174. *
Howard, Modern Drug Encyclopedia. *
Idoxuridine and Some Other Antiviral Agents (1982), Martindale, The Extra Pharmacopocia, 28th Edition, pp. 820 827. *
Korant (1979), "Inhibition of Viral Protein Cleavage", in Design of Inhibitor of Viral Functions, K. Gauri, ed., Academic Press.
Korant (1979), "Role of Cellular and Viral Proteases . . . " in The Molecular Biology of Picornoviruses, pp. 149-173.
Korant (1979), Inhibition of Viral Protein Cleavage , in Design of Inhibitor of Viral Functions, K. Gauri, ed., Academic Press. *
Korant (1979), Role of Cellular and Viral Proteases . . . in The Molecular Biology of Picornoviruses, pp. 149 173. *
Korant et al. (1974), Nature, 248:588. *
Korant et al. (1976), Jrnl. Virol., 18(1):298. *
Levandowski et al. (1982), Antimicrob. Agents Chemother., 22(6):1004. *
Levandowski, "Rhinoviruses", Chapter 16 in Textbook of Human Virology, pp. 391-405.
Levandowski, Rhinoviruses , Chapter 16 in Textbook of Human Virology, pp. 391 405. *
Marone et al. (1980), Jrn. All. Clin. Immunology, 65:171. *
Martin (1988), Antimicrob. Agents Chemother., 32:600. *
Merck Index, 9th ed., Merck and Co., Inc., 1976, p. 1310. *
Pasternak (1987), Bioscience Rep., 7(2):81. *
Phillpotts et al. (1983), Antimicrob. Agents Chemother., 23(5):671. *
Samo et al. (1984), Jrnl. Infect. Dis., 150(2):101. *
Shields (1936), "The Ionization Treatment of Hay Fever", pp. 645-648.
Shields (1936), The Ionization Treatment of Hay Fever , pp. 645 648. *
Stedman s Medical Dictionary, 23rd ed., The Williams & Wilkins Co., Baltimore, 1976, p. 807. *
Stedman's Medical Dictionary, 23rd ed., The Williams & Wilkins Co., Baltimore, 1976, p. 807.
The Pharmacological Basis of Therapeutics, 5th Edition, pp. 1000 1001. *
The Pharmacological Basis of Therapeutics, 5th Edition, pp. 1000-1001.
Tyrrell et al., "Antirhinovirus Drugs" pp. 340-341.
Tyrrell et al., Antirhinovirus Drugs pp. 340 341. *
Unpublished letter of Mr Eby s. *
Unpublished letter of Mr Eby's.
Van Voris, "Antiviral Chemotherapy", Chapter 8 in Textbook of Human Virology, pp. 193-229.
Van Voris, Antiviral Chemotherapy , Chapter 8 in Textbook of Human Virology, pp. 193 229. *
Webster s New Collegiate Dictionary (1979), lozenge and troche. *
Webster's New Collegiate Dictionary (1979), "lozenge" and troche.
Zerial et al. (1985), Antimicrob. Agents Chemother., 27(5):846. *
Zinc vs. Colds (1984), Austin American Statesman, Dec. 2, 1984, p. A15. *
Zinc Zaps Common Cold (1987), The Evening Wellington, New Zealand. *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286748A (en) * 1981-01-05 1994-02-15 Eby Iii George A General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity
US5409905A (en) * 1981-01-05 1995-04-25 Eby, Iii; George A. Cure for commond cold
US5095035A (en) * 1981-07-31 1992-03-10 Eby Iii George A Flavor stable zinc acetate compositions for oral absorption
US5728404A (en) * 1992-02-26 1998-03-17 Henkel Kommanditgesellschaft Auf Aktien Virucidal disinfectant
US5626831A (en) * 1995-12-20 1997-05-06 Van Moerkerken; Arthur Method for relief and prevention of common cold, and compositions
US5875799A (en) * 1997-09-23 1999-03-02 Advanced Medical Instruments, Inc. Therapeutic dental floss for treating systemic diseases
US20050118243A1 (en) * 1998-09-01 2005-06-02 Zicam, Llc Method and composition for delivering zinc to the nasal membrane
US6365624B1 (en) 1998-09-01 2002-04-02 Gel Tech, L.L.C. Method and composition for delivering zinc to the nasal membrane
US7989003B2 (en) * 1998-09-01 2011-08-02 Zicam, Llc Method and composition for delivering zinc to the nasal membrane
US20110077296A1 (en) * 1998-09-01 2011-03-31 Zicam, Llc Method and composition for delivering zinc to the nasal membrane
US20040109895A1 (en) * 1998-09-01 2004-06-10 Charles Hensley Method and composition for delivering zinc to the nasal membrane
US7348360B2 (en) * 1998-09-01 2008-03-25 Zicam, Llc Method and composition for delivering zinc to the nasal membrane
US20040033260A1 (en) * 1999-10-19 2004-02-19 The Procter & Gamble Company Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc
US6416744B1 (en) * 2001-06-21 2002-07-09 Colgate Palmolive Company Tooth whitening chewing gum
US7597901B2 (en) 2002-09-16 2009-10-06 Zicam, Llc System for delivering a composition to the nasal membrane and method of using the same
US20100004628A1 (en) * 2002-09-16 2010-01-07 Zicam, Llc System for delivering a composition to the nasal membrane and method of using same
US8133502B2 (en) 2002-09-16 2012-03-13 Zicam, Llc System for delivering a composition to the nasal membrane and method of using same
US7115275B2 (en) 2002-09-16 2006-10-03 Zicam, Llc System for delivering a composition to the nasal membrane and method of using same
US8236348B2 (en) 2003-02-04 2012-08-07 Bennes, Inc. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
US20050043400A1 (en) * 2003-04-30 2005-02-24 Tim Clarot Oral composition to reduce cold symptoms and duration of same
US20070092583A1 (en) * 2003-04-30 2007-04-26 Tim Clarot Cold remedy composition comprising zinc salts
US20070092552A1 (en) * 2003-04-30 2007-04-26 Tim Clarot Chewable lozenge cold remedy composition and method for making same
US7754763B2 (en) 2003-04-30 2010-07-13 Zicam, Llc Oral composition to reduce cold symptoms and duration of same
US7582418B2 (en) 2004-11-03 2009-09-01 Albion Laboratories, Inc. Antimicrobial chelates
US20070293466A1 (en) * 2004-11-03 2007-12-20 Thompson Robert C Antimicrobial Chelates
US20090081291A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User
US20090081294A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained release dosage form for lubricating an oral cavity
US9565858B2 (en) 2012-07-02 2017-02-14 Reckitt Benckiser Llc Aqueous alcoholic microbicidal compositions comprising zinc ions
US9615582B2 (en) 2012-07-02 2017-04-11 Reckitt Benckiser Llc Pressurized, sprayable aqueous alcoholic microbicidal compositions comprising zinc ions
US9775356B2 (en) 2012-07-02 2017-10-03 Reckitt Benckiser Llc Aqueous alcoholic microbicidal compositions comprising zinc ions
US9707162B2 (en) 2012-11-30 2017-07-18 Reckitt & Colman (Overseas) Limited Microbicidal personal care compositions comprising metal ions
US9034401B1 (en) 2014-01-23 2015-05-19 Matrixx Initiatives, Inc. Pharmaceutical compositions comprising plant extracts and methods for reducing duration of a common cold using same
US9555069B2 (en) 2014-01-23 2017-01-31 Matrixx Initiatives, Inc. Pharmaceutical compositions comprising plant extracts and methods for reducing duration of a common cold using same

Similar Documents

Publication Publication Date Title
Wilson et al. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home.
Sjaastad et al. “Hemicrania continua”: another headache absolutely responsive to indomethacin
Klenner Observations on the dose and administration of ascorbic acid when employed beyond the range of a vitamin in human pathology
US4466973A (en) Method of treating nasal and sinus congestion
Bouwer et al. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia
Jenner et al. Altered 5‐HT metabolism with clonazepam, diazepam and diphenylhydantoin
Eby et al. Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study.
US4661354A (en) Topical treatment of herpes simplex with a zinc sulfate-camphor water solution
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
US4285934A (en) Treatment for herpes virus
US5714505A (en) Method for treatment of psoriasis, by omeprazole or related compounds
US4381296A (en) Treatment for herpes virus
Raborn et al. Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study
US5908838A (en) Method for the treatment of acne
Jafek et al. Anosmia after intranasal zinc gluconate use
Thornhill et al. Natural treatment of perennial allergic rhinitis
Parsons Epithelial coating techniques in the treatment of interstitial cystitis
US6080783A (en) Method and composition for delivering zinc to the nasal membrane
US4835140A (en) Method for treating pneumocystis carinii pneumonia patients with clindamycin and primaquine
US4987127A (en) Method of treating a virus outbreak
Maizels et al. Intranasal lidocaine for migraine: a randomized trial and open‐label follow‐up
Weismann et al. Zinc gluconate lozenges for common cold
US4369190A (en) Analgesic composition and use thereof to ameliorate intractable pain
Gaudreault et al. Pharmacokinetics and clinical efficacy of intrarectal solution of acetaminophen
US6485727B1 (en) Method for treatment of chronic venous insufficiencies using an extract of red vine leaves

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 12

SULP Surcharge for late payment